Important update about the Boucherville plant and development center acquired by Avara
Mar 01, 2019
On February 14, 2019, Sandoz Canada requested that the Superior Court of Quebec appoint Ernst & Young Inc. as a Receiver to operate the Boucherville sterile manufacturing facility and the Development Center that Avara acquired from Sandoz in September 2018. It is pursuant to Avara Pharmaceutical Services’ default under the terms of the transaction concluded in September 2018 and its inability to financially support the continued operation of the Boucherville facility.
This process will ensure continued operation and uninterrupted supply of products to Sandoz Canada and Sandoz U.S., in line with our commitment to provide ongoing patient access to our high-quality and affordable medicines. Our priority in this matter is to maintain continuous supply of lifesaving injectable products manufactured in Avara’s Boucherville facilities to patients and customers, while supporting the local employees at the Avara Boucherville site.
We regret this unfortunate outcome of the transaction with Avara and will closely work with the Receiver to ensure the activities of the facilities are uninterrupted with minimal impact on the facilities’ employees and product supply.
